Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine.

This paper describes a preclinical study analyzing the immunogenicity and protective efficacy of Kazfluvac, an adjuvant-based inactivated pandemic influenza A/H5N1 virus vaccine. In this study, laboratory animals (ferrets and mice) were vaccinated by the intramuscular or intraperitoneal route at an interval of 14 days with two doses of the vaccine containing different concentrations of influenza virus hemagglutinin (HA) protein. HA protein without adjuvant (aluminum hydroxide and Merthiolate) was used as a control.